Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan P Foy

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|March 11, 2016
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cellsSusan P Foy, Stefanie J Mandl, Tracy dela Cruz, et al.
Nature|November 10, 2022
Non-viral precision T cell receptor replacement for personalized cell therapySusan P Foy, Kyle Jacoby, Daniela A Bota, et al.
Nature|March 8, 2023
Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapyCristina Puig-Saus, Barbara Sennino, Songming Peng, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Immunology, Immunotherapy : CII|March 11, 2016
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cellsSusan P Foy, Stefanie J Mandl, Tracy dela Cruz, et al.
Nature|November 10, 2022
Non-viral precision T cell receptor replacement for personalized cell therapySusan P Foy, Kyle Jacoby, Daniela A Bota, et al.
Nature|March 8, 2023
Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapyCristina Puig-Saus, Barbara Sennino, Songming Peng, et al.
Pageof 2